| Literature DB >> 23929535 |
Bo Liao1, Chun-Yan Hu, Tao Liu, Zheng Liu.
Abstract
OBJECTIVES/HYPOTHESIS: The role of respiratory viral infection in the pathogenesis of chronic rhinosinusitis (CRS) has been rarely studied and remains controversial. The aim of this study was to explore the prevalence of respiratory viruses in the chronic status of CRS. STUDYEntities:
Keywords: Chronic rhinosinusitis; infection; respiratory virus
Mesh:
Substances:
Year: 2013 PMID: 23929535 PMCID: PMC7165996 DOI: 10.1002/lary.24348
Source DB: PubMed Journal: Laryngoscope ISSN: 0023-852X Impact factor: 3.325
Patients' Clinical Data.
| Control | CRSwNP | CRSsNP | Control vs. CRSwNP, | Control vs. CRSsNP, | CRSsNP vs. CRSwNP, | |
|---|---|---|---|---|---|---|
| No. of patients | 53 | 67 | 61 | — | — | — |
| Male, no. (%) | 42 (79.25) | 45 (67.16) | 44 (72.13) | .141 | .379 | .542 |
| Age, yr, median (IQR) | 27 (20–43.5) | 27 (21–41) | 28 (19–39) | .853 | .537 | .459 |
| Patients with allergic rhinitis, no. (%) | 8 (15.09) | 12 (17.91) | 15 (24.59) | .681 | .208 | .355 |
| Patients with asthma, no. (%) | 2 (3.77) | 4 (5.97) | 5 (8.20) | .693 | .447 | .736 |
| Total symptoms scores, median (IQR) | 8 (5–13) | 18 (15–24) | 17 (13.5–23.5) | <.001 | <.001 | .602 |
| CT scores, median (IQR) | 0 (0–1) | 13 (9–16) | 10 (7–13) | <.001 | <.001 | .006 |
| Endoscopy scores, median (IQR) | 2 (0–3) | 7 (4–11) | 4 (3–5.5) | <.001 | <.001 | <.001 |
CT = computed tomography; CRSsNP = chronic rhinosinusitis without nasal polyps; CRSwNP = chronic rhinosinusitis with nasal polyps; IQR = interquartile range.
Primers Used for Reverse Transcription–Polymerase Chain Reaction Detection of Viruses.
| Primer | Sequences | Expected Product Size (bp) | Annealing Temperature (°C) |
|---|---|---|---|
| Picornavirus | (F) 5′‐CGGACACCCAAAGTAG‐3′ | 389 | 57 |
| (R) 5′‐GCACTTCTGTTTCCCC‐3′ | |||
| Respiratory syncytial virus | (F) 5′‐GCGATGTCTAGGTTAGGAAGAA‐3′ | 409 | 53 |
| (R) 5′‐GCTATGTCCTTGGGTAGTAAGCCT‐3′ | |||
| Influenza virus type A | (F) 5′‐AAGGGCTTTCACCGAAGAGG‐3′ | 189 | 52 |
| (R) 5′‐CCCATTCTCATTACTGCTTC‐3′ | |||
| Influenza virus type B | (F) 5′‐ATGGCCATCGGATCCTCAAC‐3′ | 240 | 57 |
| (R) 5′‐TGTCAGCTATTATGGAGCTG‐3′ | |||
| Parainfluenza virus 1 | (F) 5′‐CTTCTTGTCTGATTAATTCTG‐3′ | 450 | 57 |
| (R) 5′‐AGGATACATATCTGAATTTAAG‐3′ | |||
| Parainfluenza virus 2 | (F) 5′‐CAGCAGATTGTTGTATTATCC‐3′ | 400 | 57 |
| (R) 5′‐CAAAACATCCCAACATAACCTGTGCCGGTA‐3′ | |||
| Parainfluenza virus 3 | (F) 5′‐CTCGAGGTTGTCAGGATATAG‐3′ | 500 | 57 |
| (R) 5′‐CTTGGGAGTTGAACACAGTT‐3′ | |||
| Human coronavirus OC43 | (F) 5′‐AGGAAGGTCTGCTCCTAATTCC‐3′ | 300 | 53 |
| (R) 5′‐TGCAAAGATGGGGAACTGTGGG‐3′ | |||
| Human coronavirus 229E | (F) 5′‐GGTACTCCTAAGCCTTCTCG‐3′ | 370 | 53 |
| (R) 5′‐TGCACTAGGGTTAAGAAGAGG‐3′ | |||
| GAPDH | (F) 5′‐GGAAGATGGTGATGGGATT‐3′ | 265 | 60 |
| (R) 5′‐GAAGGTGAAGGTCGGAGTC‐3′ |
GAPDH = glyceraldehyde phosphate dehydrogenase.
Figure 1Reverse transcription–polymerase chain reaction assay of respiratory viruses. The representative pictures of electrophoresis gel results are in the left panel, lane 1, molecular size marker; lanes 2 through 4, control subjects; lanes 5 through 7, chronic rhinosinusitis with nasal polyps (CRSwNP) subjects; lanes 8 and 9, chronic rhinosinusitis without nasal polyps (CRSsNP) subjects; lane 10, negative control (distilled water); lane 11, positive control for specific viruses. The representative pictures of electrophoresis gel results are in the right panel, lane 1, molecular size marker; lane 2, negative control (distilled water); lanes 3 through 5, control subjects; lanes 6 through 8, CRSwNP subjects; lanes 9 and 10, CRSsNP subjects; lane 11, positive control for specific viruses.
Identification Rate of Virus.
| Virus | Control, No. (%), n = 53 | CRSwNP, No. (%), n = 67 | CRSsNP, No. (%), n = 61 |
|
|---|---|---|---|---|
| Picornavirus | 25 (49.17) | 24 (35.82) | 17 (27.87) | .101 |
| Respiratory syncytial virus | 10 (18.87) | 10 (14.93) | 5 (8.20) | .244 |
| Influenza virus type A | 14 (26.42) | 10 (14.93) | 10 (16.39) | .234 |
| Influenza virus type B | 6 (11.32) | 8 (11.94) | 12 (19.67) | .347 |
| Parainfluenza virus 1 | 12 (22.64) | 10 (14.93) | 6 (9.84) | .167 |
| Parainfluenza virus 2 | 6 (11.32) | 2 (2.99) | 4 (6.56) | .190 |
| Parainfluenza virus 3 | 2 (3.77) | 10 (14.93) | 8 (13.11) | .126 |
| Human coronavirus 229E | 6 (11.32) | 2 (2.99) | 2 (3.28) | .089 |
| Human coronavirus OC43 | 12 (22.64) | 8 (11.94) | 6 (9.84) | .117 |
| Positive of any of these viruses | 40 (75.47) | 46 (68.66) | 45 (73.77) | .678 |
CRSsNP = chronic rhinosinusitis without nasal polyps; CRSwNP = chronic rhinosinusitis with nasal polyps.
The Frequency of Co‐colonization of Different Types of Viruses.
| Control, No. (%), n = 53 | CRSwNP, No. (%), n = 67 | CRSsNP, No. (%), n = 61 |
| |
|---|---|---|---|---|
| Single virus | 16 (30.19) | 22 (32.84) | 25 (40.98) | 0.441 |
| Multiple viruses (>1 virus) | 24 (45.29) | 24 (35.82) | 20 (32.79) | 0.350 |
| 2 species | 8 (15.09) | 11 (16.42) | 10 (16.39) | 0.976 |
| 3 species | 12 (22.64) | 12 (17.91) | 6 (9.84) | 0.174 |
| ≥4 species | 4 (7.55) | 1 (1.49) | 4 (6.56) | 0.237 |
CRSsNP = chronic rhinosinusitis without nasal polyps; CRSwNP = chronic rhinosinusitis with nasal polyps.
Clinical Disease Severity in Viral Positive and Negative Subjects.
| Control | CRSwNP | CRSsNP | |||||||
|---|---|---|---|---|---|---|---|---|---|
| VirusPositive, n = 40 | Virus Negative, n = 13 |
| Virus Positive, n = 46 | Virus Negative, n = 21 |
| Virus Positive, n = 45 | Virus Negative, n = 16 |
| |
| Male, no. (%) | 31 (77.50) | 11 (84.62) | .711 | 34 (73.91) | 15 (71.43) | .831 | 33 (73.33) | 11 (68.75) | .725 |
| Age, yr, median (IQR) | 30.5 (21.25–42.75) | 26 (19–45.5) | .521 | 34.5 (22–41.25) | 26 (18–39.5) | .368 | 28 (17.5–38.5) | 29 (21–42.75) | .496 |
| Patients with allergic rhinitis, no. (%) | 6 (15) | 1 (7.69) | .667 | 11 (23.91) | 2 (9.52) | .203 | 11 (24.44) | 4 (25) | .965 |
| Patients with asthma, no. (%) | 1 (2.5) | 1 (7.69) | .434 | 3 (6.52) | 1 (4.76) | 1.000 | 4 (8.89) | 1 (6.25) | 1.000 |
| Total VAS scores, median (IQR) | 8 (5–12.75) | 9 (6.5–15.5) | .604 | 18 (14.75–24) | 18 (15.5–19.5) | .555 | 17 (13.5–24) | 17 (13.25–21.75) | .611 |
| CT scores, median (IQR) | 0 (0–1) | 0 (0–0) | .267 | 12 (8.75–15) | 13 (8.5–17.5) | .551 | 12 (7–15) | 8.5 (7–10.75) | .177 |
| Endoscopy scores, median (IQR) | 2 (0–2.75) | 2 (0–4) | .669 | 6 (4–10) | 8 (5–12) | .219 | 4 (3–5) | 4 (2.25–6) | .860 |
CT = computed tomography; CRSsNP = chronic rhinosinusitis without nasal polyps; CRSwNP = chronic rhinosinusitis with nasal polyps; IQR = interquartile range; VAS = visual analog scale.